Home > Insider Trading > Filing (0001628280-24-010750)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
834365	Biolife Solutions Inc	BLFS	Electromedical & Electrotherapeutic Apparatus (3845)	943076866

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1633186	Todd Berard	3303 Monte Villa Parkway Suite 310 Bothell WA 98021	Chief Marketing Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-03-08	14,456	$0.00	130,144	No	4	A	Direct
Common Stock	Acquisiton	2024-03-08	17,523	$0.00	147,667	No	4	A	Direct
Common Stock	Disposition	2024-03-11	401	$17.42	147,266	No	4	S	Direct
Common Stock	Disposition	2024-03-12	7,107	$16.60	140,159	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.
The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.